Concepts (246)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 27 | 2025 | 302 | 4.060 |
Why?
|
| Heart Valve Prosthesis Implantation | 6 | 2024 | 26 | 2.750 |
Why?
|
| Cardiovascular Diseases | 15 | 2026 | 749 | 2.530 |
Why?
|
| Heart Valve Prosthesis | 5 | 2024 | 44 | 2.050 |
Why?
|
| Mitral Valve | 4 | 2024 | 36 | 1.770 |
Why?
|
| Ventricular Function, Left | 9 | 2025 | 114 | 1.730 |
Why?
|
| Stroke Volume | 15 | 2021 | 122 | 1.710 |
Why?
|
| Thrombosis | 3 | 2024 | 81 | 1.530 |
Why?
|
| Ventricular Remodeling | 4 | 2023 | 61 | 1.490 |
Why?
|
| Myocardial Infarction | 4 | 2023 | 247 | 1.420 |
Why?
|
| Mitral Valve Insufficiency | 3 | 2021 | 22 | 1.410 |
Why?
|
| Registries | 16 | 2025 | 437 | 1.340 |
Why?
|
| Aortic Valve Stenosis | 5 | 2023 | 33 | 1.320 |
Why?
|
| Postoperative Complications | 2 | 2024 | 263 | 1.290 |
Why?
|
| Singapore | 18 | 2025 | 33 | 1.270 |
Why?
|
| Coronary Artery Disease | 4 | 2025 | 163 | 1.160 |
Why?
|
| Prosthesis Design | 3 | 2024 | 47 | 1.080 |
Why?
|
| Middle Aged | 45 | 2026 | 12222 | 0.940 |
Why?
|
| Humans | 71 | 2026 | 43102 | 0.940 |
Why?
|
| Aged | 36 | 2025 | 8214 | 0.930 |
Why?
|
| Exercise Tolerance | 2 | 2015 | 22 | 0.900 |
Why?
|
| Bioprosthesis | 1 | 2024 | 5 | 0.890 |
Why?
|
| Hospitalization | 9 | 2025 | 485 | 0.870 |
Why?
|
| Quality of Life | 8 | 2021 | 616 | 0.850 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2021 | 760 | 0.820 |
Why?
|
| Male | 52 | 2026 | 23409 | 0.810 |
Why?
|
| Risk Factors | 19 | 2025 | 3994 | 0.800 |
Why?
|
| Treatment Outcome | 12 | 2024 | 1604 | 0.790 |
Why?
|
| Risk Assessment | 9 | 2025 | 863 | 0.790 |
Why?
|
| Aortic Valve | 5 | 2023 | 38 | 0.790 |
Why?
|
| Prospective Studies | 17 | 2021 | 1600 | 0.780 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2026 | 989 | 0.750 |
Why?
|
| Asia | 12 | 2025 | 98 | 0.740 |
Why?
|
| Exercise Test | 3 | 2018 | 74 | 0.700 |
Why?
|
| Stroke | 2 | 2023 | 340 | 0.680 |
Why?
|
| Female | 46 | 2026 | 24698 | 0.680 |
Why?
|
| Myocardium | 2 | 2023 | 263 | 0.670 |
Why?
|
| Air Pollutants | 2 | 2019 | 130 | 0.660 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 193 | 0.650 |
Why?
|
| Coronary Vessels | 2 | 2018 | 92 | 0.650 |
Why?
|
| Jugular Veins | 1 | 2020 | 7 | 0.650 |
Why?
|
| Catheterization, Central Venous | 1 | 2020 | 9 | 0.650 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2025 | 375 | 0.630 |
Why?
|
| Macrophages | 3 | 2023 | 529 | 0.610 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2020 | 96 | 0.590 |
Why?
|
| Calcinosis | 1 | 2019 | 62 | 0.590 |
Why?
|
| Particulate Matter | 1 | 2019 | 83 | 0.560 |
Why?
|
| Immunity, Innate | 1 | 2019 | 171 | 0.550 |
Why?
|
| Time Factors | 8 | 2024 | 1857 | 0.530 |
Why?
|
| Electrocardiography | 5 | 2021 | 185 | 0.510 |
Why?
|
| Financial Management | 1 | 2016 | 6 | 0.500 |
Why?
|
| Long QT Syndrome | 1 | 2016 | 15 | 0.490 |
Why?
|
| Marketing | 1 | 2016 | 45 | 0.490 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 2025 | 43 | 0.480 |
Why?
|
| Tetralogy of Fallot | 1 | 2014 | 5 | 0.440 |
Why?
|
| Pulmonary Valve Insufficiency | 1 | 2014 | 8 | 0.440 |
Why?
|
| Death, Sudden, Cardiac | 4 | 2018 | 31 | 0.440 |
Why?
|
| Walking | 1 | 2015 | 88 | 0.440 |
Why?
|
| Sex Factors | 8 | 2019 | 1028 | 0.420 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2014 | 54 | 0.420 |
Why?
|
| Adult | 19 | 2026 | 13872 | 0.420 |
Why?
|
| Diabetes Mellitus | 4 | 2022 | 539 | 0.410 |
Why?
|
| Predictive Value of Tests | 5 | 2019 | 440 | 0.410 |
Why?
|
| Emotions | 1 | 2016 | 254 | 0.400 |
Why?
|
| Attitude of Health Personnel | 2 | 2026 | 231 | 0.400 |
Why?
|
| Recovery of Function | 3 | 2024 | 107 | 0.390 |
Why?
|
| Aged, 80 and over | 7 | 2024 | 2853 | 0.380 |
Why?
|
| Prosthesis Failure | 2 | 2024 | 19 | 0.380 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 4 | 2020 | 78 | 0.370 |
Why?
|
| Proportional Hazards Models | 7 | 2025 | 518 | 0.330 |
Why?
|
| Atrial Fibrillation | 3 | 2021 | 122 | 0.330 |
Why?
|
| Anticoagulants | 2 | 2023 | 122 | 0.330 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2021 | 23 | 0.320 |
Why?
|
| Echocardiography | 6 | 2021 | 167 | 0.310 |
Why?
|
| Heart | 2 | 2023 | 184 | 0.310 |
Why?
|
| Prognosis | 7 | 2021 | 861 | 0.300 |
Why?
|
| Hypertension | 3 | 2025 | 835 | 0.300 |
Why?
|
| Diabetic Angiopathies | 2 | 2019 | 26 | 0.290 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 2 | 2025 | 65 | 0.290 |
Why?
|
| Retrospective Studies | 7 | 2024 | 2544 | 0.280 |
Why?
|
| Prevalence | 7 | 2025 | 1612 | 0.280 |
Why?
|
| Acute Coronary Syndrome | 2 | 2025 | 42 | 0.260 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2025 | 45 | 0.250 |
Why?
|
| Hypoglycemic Agents | 2 | 2019 | 184 | 0.250 |
Why?
|
| Cohort Studies | 5 | 2023 | 1759 | 0.250 |
Why?
|
| Cause of Death | 4 | 2019 | 186 | 0.250 |
Why?
|
| Myocardial Ischemia | 2 | 2025 | 83 | 0.250 |
Why?
|
| Mortality | 2 | 2019 | 175 | 0.240 |
Why?
|
| Practice Guidelines as Topic | 2 | 2025 | 223 | 0.240 |
Why?
|
| Cross-Sectional Studies | 6 | 2026 | 3156 | 0.240 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2025 | 22 | 0.240 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2025 | 51 | 0.220 |
Why?
|
| Heart Valve Diseases | 1 | 2024 | 15 | 0.220 |
Why?
|
| Health Status | 2 | 2019 | 442 | 0.220 |
Why?
|
| Developing Countries | 1 | 2025 | 113 | 0.220 |
Why?
|
| Adrenergic beta-Antagonists | 3 | 2019 | 54 | 0.220 |
Why?
|
| Cerebrovascular Disorders | 1 | 2024 | 43 | 0.210 |
Why?
|
| Young Adult | 4 | 2019 | 5080 | 0.210 |
Why?
|
| Heart Ventricles | 1 | 2025 | 123 | 0.210 |
Why?
|
| Age Factors | 5 | 2019 | 1154 | 0.210 |
Why?
|
| RNA | 1 | 2025 | 266 | 0.200 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2025 | 384 | 0.200 |
Why?
|
| Health Personnel | 1 | 2026 | 277 | 0.200 |
Why?
|
| Hemorrhage | 1 | 2023 | 55 | 0.200 |
Why?
|
| Phenotype | 3 | 2022 | 780 | 0.190 |
Why?
|
| Warfarin | 1 | 2023 | 67 | 0.190 |
Why?
|
| Administration, Oral | 1 | 2023 | 260 | 0.190 |
Why?
|
| Inflammation | 3 | 2023 | 758 | 0.190 |
Why?
|
| Kidney Transplantation | 1 | 2023 | 101 | 0.190 |
Why?
|
| Blood Pressure | 1 | 2025 | 666 | 0.170 |
Why?
|
| Surgical Instruments | 1 | 2021 | 7 | 0.170 |
Why?
|
| Salvia | 1 | 2020 | 10 | 0.170 |
Why?
|
| Hair Follicle | 1 | 2020 | 12 | 0.170 |
Why?
|
| Patient Readmission | 2 | 2022 | 122 | 0.170 |
Why?
|
| Europe | 3 | 2025 | 115 | 0.170 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2025 | 497 | 0.170 |
Why?
|
| Reoperation | 1 | 2020 | 34 | 0.160 |
Why?
|
| Scleroderma, Systemic | 1 | 2019 | 12 | 0.160 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2019 | 13 | 0.160 |
Why?
|
| Feasibility Studies | 1 | 2021 | 259 | 0.160 |
Why?
|
| Fractional Flow Reserve, Myocardial | 2 | 2018 | 21 | 0.160 |
Why?
|
| Sulfur Dioxide | 1 | 2019 | 9 | 0.150 |
Why?
|
| Nitrogen Dioxide | 1 | 2019 | 17 | 0.150 |
Why?
|
| Microvessels | 1 | 2019 | 31 | 0.150 |
Why?
|
| Ozone | 1 | 2019 | 26 | 0.150 |
Why?
|
| Sulfonylurea Compounds | 1 | 2019 | 17 | 0.150 |
Why?
|
| Comorbidity | 5 | 2019 | 737 | 0.150 |
Why?
|
| Carbon Monoxide | 1 | 2019 | 47 | 0.150 |
Why?
|
| Hypertension, Pulmonary | 1 | 2019 | 78 | 0.150 |
Why?
|
| Oxygen Consumption | 2 | 2018 | 110 | 0.140 |
Why?
|
| Heart Diseases | 1 | 2019 | 112 | 0.140 |
Why?
|
| Cost of Illness | 1 | 2018 | 98 | 0.140 |
Why?
|
| Heart Rate | 2 | 2018 | 266 | 0.140 |
Why?
|
| Sphingolipids | 1 | 2018 | 14 | 0.140 |
Why?
|
| Air Pollution | 1 | 2019 | 87 | 0.140 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2018 | 11 | 0.140 |
Why?
|
| Metformin | 1 | 2019 | 75 | 0.140 |
Why?
|
| Guideline Adherence | 1 | 2018 | 98 | 0.140 |
Why?
|
| Linear Models | 2 | 2016 | 317 | 0.140 |
Why?
|
| Societies, Medical | 1 | 2018 | 74 | 0.140 |
Why?
|
| Anemia | 1 | 2018 | 55 | 0.140 |
Why?
|
| Interleukin-1 | 1 | 2017 | 39 | 0.130 |
Why?
|
| Sleep | 1 | 2019 | 185 | 0.130 |
Why?
|
| Survival Rate | 4 | 2021 | 355 | 0.130 |
Why?
|
| Republic of Korea | 1 | 2017 | 141 | 0.130 |
Why?
|
| Coronary Artery Bypass | 1 | 2017 | 47 | 0.130 |
Why?
|
| Plant Extracts | 1 | 2020 | 302 | 0.130 |
Why?
|
| Genome-Wide Association Study | 1 | 2019 | 423 | 0.130 |
Why?
|
| Defibrillators, Implantable | 1 | 2017 | 39 | 0.130 |
Why?
|
| Primary Prevention | 1 | 2017 | 63 | 0.130 |
Why?
|
| Insulin | 1 | 2019 | 258 | 0.130 |
Why?
|
| Public Health | 2 | 2018 | 424 | 0.130 |
Why?
|
| Obesity | 3 | 2019 | 1151 | 0.120 |
Why?
|
| Heart Conduction System | 1 | 2016 | 15 | 0.120 |
Why?
|
| Complementary Therapies | 1 | 2016 | 51 | 0.120 |
Why?
|
| Odds Ratio | 1 | 2017 | 587 | 0.120 |
Why?
|
| Infant, Newborn | 1 | 2019 | 972 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 734 | 0.120 |
Why?
|
| Adolescent | 2 | 2019 | 6081 | 0.120 |
Why?
|
| Infant | 1 | 2019 | 1175 | 0.120 |
Why?
|
| Atherosclerosis | 1 | 2017 | 169 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 245 | 0.110 |
Why?
|
| Models, Theoretical | 1 | 2016 | 232 | 0.110 |
Why?
|
| Child, Preschool | 1 | 2019 | 1546 | 0.110 |
Why?
|
| Ventricular Function, Right | 1 | 2014 | 33 | 0.110 |
Why?
|
| Aging | 1 | 2019 | 783 | 0.100 |
Why?
|
| Sex Characteristics | 1 | 2016 | 258 | 0.100 |
Why?
|
| Animals | 5 | 2025 | 16992 | 0.100 |
Why?
|
| United States | 3 | 2018 | 5205 | 0.090 |
Why?
|
| Body Mass Index | 3 | 2023 | 925 | 0.090 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 1081 | 0.090 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2011 | 24 | 0.090 |
Why?
|
| Child | 1 | 2019 | 3443 | 0.080 |
Why?
|
| Influenza, Human | 1 | 2011 | 92 | 0.080 |
Why?
|
| Population Surveillance | 1 | 2011 | 246 | 0.080 |
Why?
|
| Severity of Illness Index | 3 | 2018 | 719 | 0.080 |
Why?
|
| Health Status Disparities | 1 | 2016 | 719 | 0.080 |
Why?
|
| Follow-Up Studies | 2 | 2025 | 1067 | 0.070 |
Why?
|
| Asia, Southeastern | 2 | 2019 | 12 | 0.070 |
Why?
|
| Incidence | 3 | 2018 | 1078 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2025 | 1285 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 2 | 2025 | 1869 | 0.070 |
Why?
|
| Mice | 3 | 2025 | 6644 | 0.070 |
Why?
|
| Delphi Technique | 1 | 2025 | 34 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 638 | 0.050 |
Why?
|
| Patient Satisfaction | 1 | 2025 | 165 | 0.050 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 1063 | 0.050 |
Why?
|
| Bystander Effect | 1 | 2023 | 15 | 0.050 |
Why?
|
| Myocytes, Cardiac | 1 | 2025 | 183 | 0.050 |
Why?
|
| Thinness | 1 | 2023 | 32 | 0.050 |
Why?
|
| Hong Kong | 1 | 2022 | 29 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2025 | 2157 | 0.050 |
Why?
|
| Vaccination | 1 | 2025 | 355 | 0.050 |
Why?
|
| Testis | 1 | 2023 | 207 | 0.050 |
Why?
|
| Mice, Transgenic | 1 | 2023 | 665 | 0.040 |
Why?
|
| Hair | 1 | 2020 | 38 | 0.040 |
Why?
|
| Lipids | 1 | 2022 | 256 | 0.040 |
Why?
|
| Ventricular Function | 1 | 2019 | 8 | 0.040 |
Why?
|
| Waist-Hip Ratio | 1 | 2019 | 34 | 0.040 |
Why?
|
| Asia, Western | 1 | 2019 | 5 | 0.040 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2019 | 5 | 0.040 |
Why?
|
| Waist Circumference | 1 | 2019 | 90 | 0.040 |
Why?
|
| Telomere | 1 | 2019 | 59 | 0.040 |
Why?
|
| Smoking Cessation | 1 | 2026 | 590 | 0.040 |
Why?
|
| Diuretics | 1 | 2019 | 51 | 0.040 |
Why?
|
| Sweden | 1 | 2018 | 18 | 0.040 |
Why?
|
| Social Class | 1 | 2021 | 291 | 0.040 |
Why?
|
| Internationality | 1 | 2018 | 37 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2018 | 115 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 107 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2018 | 207 | 0.030 |
Why?
|
| Adiposity | 1 | 2019 | 157 | 0.030 |
Why?
|
| Seasons | 1 | 2018 | 139 | 0.030 |
Why?
|
| New York | 1 | 2018 | 93 | 0.030 |
Why?
|
| Lipid Metabolism Disorders | 1 | 2017 | 5 | 0.030 |
Why?
|
| Smad3 Protein | 1 | 2017 | 12 | 0.030 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2017 | 10 | 0.030 |
Why?
|
| Geography | 1 | 2018 | 110 | 0.030 |
Why?
|
| Interleukin-18 | 1 | 2017 | 17 | 0.030 |
Why?
|
| Cardiomegaly | 1 | 2018 | 44 | 0.030 |
Why?
|
| France | 1 | 2017 | 23 | 0.030 |
Why?
|
| Morbidity | 1 | 2017 | 97 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 1124 | 0.030 |
Why?
|
| China | 1 | 2018 | 229 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2018 | 102 | 0.030 |
Why?
|
| Length of Stay | 1 | 2018 | 229 | 0.030 |
Why?
|
| Canada | 1 | 2017 | 163 | 0.030 |
Why?
|
| India | 1 | 2017 | 108 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2020 | 1621 | 0.030 |
Why?
|
| Massachusetts | 1 | 2016 | 35 | 0.030 |
Why?
|
| Insulin Resistance | 1 | 2018 | 201 | 0.030 |
Why?
|
| Life Style | 1 | 2018 | 334 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2017 | 187 | 0.030 |
Why?
|
| Australia | 1 | 2015 | 103 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2015 | 100 | 0.030 |
Why?
|
| Educational Status | 1 | 2017 | 339 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2020 | 1455 | 0.030 |
Why?
|
| Action Potentials | 1 | 2016 | 246 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2016 | 760 | 0.020 |
Why?
|
| Exercise | 1 | 2018 | 692 | 0.020 |
Why?
|
| Sentinel Surveillance | 1 | 2011 | 25 | 0.020 |
Why?
|
| Seroepidemiologic Studies | 1 | 2011 | 74 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2011 | 126 | 0.020 |
Why?
|
| Health Promotion | 1 | 2017 | 704 | 0.020 |
Why?
|
| Apoptosis | 1 | 2017 | 1568 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 611 | 0.020 |
Why?
|